Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib Combinations in Advanced Osteosarcoma
NCT04044378Phase 2Withdrawn
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famitinib in osteosarcoma (OS), sponsored by Peking University People's Hospital. Planned start Aug 2019; status: withdrawn.
02
Drugs
famitinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04044378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044378.